[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Asociación para Evitar la Ceguera en México\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,79,99,124,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100626015","blink-reminders-and-meibomian-gland-loss-in-digital-screen-users-100626015",false,"NCT07430137","Blink Reminders and Meibomian Gland Loss in Digital Screen Users","Effect of a Blink Reminder Program on the Progression of Meibomian Gland Loss in Intensive Digital Screen Users: a Randomized Controlled Trial With Infrared Meibography","Inclusion Criteria:\n\n* Participants aged 18 to 40 years.\n* Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week.\n* Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms).\n* Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography.\n* Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis.\n* Technical ability to install and operate the BlinkEasy software on their primary digital device.\n\nExclusion Criteria:\n\n* Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis.\n* History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury.\n* Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months.\n* Active use of contact lenses that cannot be suspended for the duration of the 12-week study period.\n* Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis).\n* Diagnosis of Diabetes Mellitus (Type 1 or Type 2).","ALL","18 Years","40 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).",[27,28],"Dry Eye Syndromes","Meibomian Gland Dysfunction (Disorder)",[30,31,32,33,34,35],"Dry eye","Blinking","Meibography","Digital Displays","Meibomian Gland Atrophy","BlinkEasy","NOT_YET_RECRUITING","2026-02-25",{"date":39,"type":40},"2026-02-27","ACTUAL",{"date":42,"type":21},"2026-02-19",{"date":44,"type":21},"2026-08",{"name":46,"class":47},"Asociación para Evitar la Ceguera en México","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100488166","phase-1-study-to-assess-safety-and-tolerability-of-multiple-doses-of-eo2002-100488166","NCT05636579","Study to Assess Safety and Tolerability of Multiple Doses of EO2002","Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema","Inclusion Criteria:\n\nAll ocular criteria apply to the study eye unless otherwise noted.\n\n1. Age ≥ 18 years.\n2. Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus).\n3. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy.\n\nKey Exclusion Criteria:\n\nAll ocular criteria apply to the study eye unless otherwise noted.\n\n1. Other corneal disease\n2. Anterior chamber intraocular lens\n3. Sutured or scleral-fixated intraocular lens.\n4. Macular disease that in the investigator and\u002For sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.\n5. History of refractive surgery.\n6. History of Vitrectomy\n7. Descemet membrane detachment.\n8. History of uveitis or other ocular inflammatory disease.\n9. History of incisional glaucoma surgery (e.g.,trabeculectomy, glaucoma drainage implant).\n10. IOP \\>21 or \\\u003C7 mm Hg\n11. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.\n\n11\\. History of ocular neoplasm. 12. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20\u002F200).\n\n13\\. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.\n\n14\\. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.\n\n15\\. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.",{"count":56,"type":21},12,[58],"PHASE1","The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.",[61,62,63,64,65,66,67,68],"Corneal Edema","Corneal Endothelial Dystrophy","Endothelial Dysfunction","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","Bullous Keratopathy","Pseudophakic Bullous Keratopathy","Corneal Edema Pseudophakic","RECRUITING","2025-12-02",{"date":72,"type":40},"2025-12-08",{"date":74,"type":40},"2022-11-08",{"date":76,"type":21},"2025-12-09",{"name":46,"class":47},1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":78},"100484374","phase-1-safety-and-tolerability-of-eo2002-100484374","NCT05587205","Safety and Tolerability of EO2002","Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery","Key Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.\n3. Decreased endothelial cell count\n\nExclusion Criteria:\n\nAll ocular criteria apply to study eye unless otherwise noted.\n\n1. Other corneal disease\n2. Macular disease that in the investigator and\u002For sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.\n3. Descemet membrane detachment.\n4. History of uveitis or other ocular inflammatory disease.\n5. History of incisional glaucoma surgery\n6. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.\n7. History of ocular neoplasm.\n8. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20\u002F200).\n9. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.\n10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.\n11. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.",{"count":87,"type":21},32,[58],"The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.",[91,92],"Cataract","Endothelial Cell Loss, Corneal",{"date":72,"type":40},{"date":95,"type":40},"2022-08-30",{"date":97,"type":21},"2026-10-06",{"name":46,"class":47},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":108,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":78},"100606419","vascular-changes-associated-with-endophthalmitis-100606419","NCT07175311","Vascular Changes Associated With Endophthalmitis.","Inclusion Criteria:\n\n* Patients with a history of endophthalmitis Diagnosis of Endophthalmitis\n* Clinical symptoms: Pain, decrease in visual acuity, anterior chamber cells and\u002For vitreous turbidity, corneal edema, conjunctival hyperemia\n* Laboratory studies: B-mode USG and or positive culture\n* Patients who meet the endophthalmitis resolution criteria of the Mexican Endophthalmitis Study Group\n* Patients with previously signed informed consent\n\nExclusion Criteria:\n\n* Patients who have not signed the informed consent\n* Patients under 18 years.\n* Patients with endophthalmitis who do not meet the resolution criteria of the Mexican Endophthalmitis Study Group",true,{"count":107,"type":21},71,"6 Weeks","OBSERVATIONAL","This study aims to describe and investigate vascular changes associated with exogenous endophthalmitis, as well as to create a photo library where they are evidenced",[112],"Endophthalmitis",[114,115],"Postoperative endophthalmitis","Multimodal imaging","2025-09-09",{"date":118,"type":40},"2025-09-16",{"date":120,"type":40},"2024-11-01",{"date":122,"type":21},"2026-03-01",{"name":46,"class":47},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":78},"100600316","post-surgical-functional-results-in-patients-with-epiretinal-membrane-undergoing-controlled-macular-detachment-100600316","NCT07095907","Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment","Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment: Pilot Study.","DMER25","Inclusion Criteria:\n\n* Patients over 18 years of age.\n* Patients with a confirmed diagnosis of ERM grade III or IV by Optical Coherence Tomography who present visual disturbances such as metamorphopsia or visual impairment (measured in letters on the ETDRS scale) but who do not reflect end-stage visual impairment.\n* Patients suitable for vitreoretinal surgical procedures, with no uncontrolled medical comorbidities that contraindicate surgery.\n* Patients who understand the objectives and risks of the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with a confirmed diagnosis of grade III or IV ERM by Optical Coherence Tomography who do not have the ability to improve their visual acuity.\n* Patients diagnosed with ocular pathologies that significantly affect their visual acuity, such as moderate or advanced glaucoma, non-glaucomatous optic neuropathies, or optic media opacities such as leukomas, significant corneal edema, or other maculopathies such as macular atrophy or macular ischemia.",{"count":133,"type":21},36,[24],"This study aims to evaluate postsurgical functional changes in patients with advanced epiretinal membrane (ERM) (stages 3 and 4) by integrating a controlled macular detachment with a balanced salt solution to the conventional ERM peeling technique.",[137],"Epiretinal Membrane Surgery",[139,140,141],"Epiretinal membrane","Epiretinal membrane surgery","Macular detachment","2025-07-29",{"date":144,"type":40},"2025-07-31",{"date":146,"type":40},"2025-06-10",{"date":148,"type":21},"2026-01-26",{"name":46,"class":47},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":156,"maxAge":157,"enrollmentInfo":4,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":78},"100083677","phase-2-antiangiogenic-therapy-with-bevacizumab-in-retinopathy-of-prematurity-structural-outcome-100083677","NCT00346814","Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome","Inclusion Criteria:\n\n* Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY\n\nExclusion Criteria:\n\n* PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER","1 Month","12 Months",[159,160],"PHASE2","PHASE3","Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity",[163],"Retinopathy of Prematurity",[165,166],"Retinopathy of prematurity","antiangiogenic therapy","2024-07-30",{"date":169,"type":40},"2024-07-31",{"date":171,"type":40},"2007-07",{"date":173,"type":21},"2024-11",{"name":46,"class":47},""]